The MRP is Rs 7,950 per vial and patients will typically need four vials. All around, it is likely to cost Rs 32,000 at the most

New Delhi: In a watershed moment, the Drug Controller General of India (DCGI) has approved Biocon Ltd’s Itolizumab drug for emergency treatment of COVID-19 patients.

A press release from Biocon said, “Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb® for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19.”

The drug which is already been used to treat psoriasis, will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.

Also Read: BREAKING: Aishwarya Rai, daughter Aaradhya test positive for COVID-19

Kiran Mazumdar-Shar, executive chairperson, Biocon, expressing happiness over the successful outcome said, “I am confident that this ‘first-in-class’ biologic will save lives and help reduce the mortality rate in our country.

She added, “This positions India amongst the leading global innovators in their effort to overcome the COVID-19 pandemic.”

According to reports, the MRP is Rs 7,950 per vial and patients will typically need four vials. All around, it is likely to cost Rs 32,000 at the most.

Also Read: WATCH | How 2 Arunachal locals entered Tibet through ‘India-China border’

Leave a comment

Leave a comment